Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

| Create an account https://orcid.org

Search life-sciences literature (45,104,206 articles, preprints and more)

Search results

1-25 of 110 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Paz-Ares L, Goto Y, Wan-Teck Lim D, Halmos B, Chul Cho B, Cobo M, Luis González Larriba J, Zhou C, Demedts I, Atmaca A, Baka S, Mookerjee B, Portella S, Zhu Z, Wu J, Demanse D, Dharan B, Reck M
Lung Cancer, 189:107451, 16 Jan 2024
Cited by: 3 articles | PMID: 38354535
Add to export list
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Hauschild A, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, Blank CU, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A, Gasal E, Mookerjee B, Chapman PB
Eur J Cancer, 125:114-120, 01 Jan 2020
Cited by: 33 articles | PMID: 31864178 | PMCID: PMC8073226
Add to export list Free full text in Europe PMC
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, [...] Grob JJ
Ann Oncol, 30(11):1848, 01 Nov 2019
Cited by: 18 articles | PMID: 31406976 | PMCID: PMC6927319
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O
Nat Med, 25(6):936-940, 06 Jun 2019
Cited by: 174 articles | PMID: 31171879 | PMCID: PMC8562134
Add to export list Free full text in Europe PMC
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O
Nat Med, 25(8):1319, 01 Aug 2019
Cited by: 4 articles | PMID: 31267021
Add to export list
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A
Nat Med, 25(6):941-946, 06 Jun 2019
Cited by: 155 articles | PMID: 31171878
Add to export list
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF^V600E or BRAF^V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, [...] Long GV
Lancet Oncol, 20(5):701-710, 27 Mar 2019
Cited by: 24 articles | PMID: 30928620
Add to export list
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A, Mookerjee B, Schadendorf D
Eur J Cancer, 109:61-69, 25 Jan 2019
Cited by: 33 articles | PMID: 30690294
Add to export list
RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG)
Wen P, Alexander S, Yung-Jue B, van den Bent M, Gazzah A, Dietrich S, de Vos F, van Linde M, Lai A, Chi A, Prager G, Campone M, von Bubnoff N, Fasolo A, Lopez-Martin J, Mookerjee B, Boran A, Burgess P, Rangwala F, Subbiah V
Neuro Oncol, 20(suppl 6):vi238-vi238, 01 Nov 2018
Cited by: 0 articles | PMCID: PMC6217670
Add to export list Free full text in Europe PMC
RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG)
Wen P, De Greve J, Mason W, Hofheinz R, Dietrich S, de Vos F, van den Bent M, Mookerjee B, Boran A, Burgess P, Rangwala F, Gazzah A
Neuro Oncol, 20(suppl 6):vi238-vi239, 01 Nov 2018
Cited by: 0 articles | PMCID: PMC6217698
Add to export list Free full text in Europe PMC
LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB
Bouffet E, Kieran M, Hargrave D, Roberts S, Aerts I, Broniscer A, Geoerger B, Dasgupta K, Tseng L, Russo M, Mookerjee B, Moertel C
Neuro Oncol, 20(suppl 2):i114-i114, 01 Jun 2018
Cited by: 0 articles | PMCID: PMC6012791
Add to export list Free full text in Europe PMC
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF^V600E-Mutant Colorectal Cancer.
Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, [...] Van Cutsem E
Cancer Discov, 8(4):428-443, 05 Feb 2018
Cited by: 273 articles | PMID: 29431699 | PMCID: PMC5882509
Add to export list Free full text in Europe PMC
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Nebot N, Arkenau HT, Infante JR, Chandler JC, Weickhardt A, Lickliter JD, Sarantopoulos J, Gordon MS, Mak G, St-Pierre A, Tang L, Mookerjee B, Carson SW, Hayes S, Grossmann KF
Br J Clin Pharmacol, 84(4):764-775, 23 Jan 2018
Cited by: 8 articles | PMID: 29243287 | PMCID: PMC5867134
Add to export list Free full text in Europe PMC
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B
J Clin Oncol, 36(1):7-13, 26 Oct 2017
Cited by: 404 articles | PMID: 29072975 | PMCID: PMC5791845
Add to export list Free full text in Europe PMC
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT
J Clin Oncol, 36(7):667-673, 09 Oct 2017
Cited by: 107 articles | PMID: 28991513 | PMCID: PMC10466457
Add to export list Free full text in Europe PMC
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, [...] Kirkwood JM
N Engl J Med, 377(19):1813-1823, 10 Sep 2017
Cited by: 607 articles | PMID: 28891408
Add to export list
Dabrafenib plus trametinib in patients with previously untreated BRAF^V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol, 18(10):1307-1316, 11 Sep 2017
Cited by: 439 articles | PMID: 28919011
Add to export list
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, [...] Grob JJ
Ann Oncol, 28(7):1631-1639, 01 Jul 2017
Cited by: 304 articles | PMID: 28475671 | PMCID: PMC5834102
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Dabrafenib plus trametinib in patients with BRAF^V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV
Lancet Oncol, 18(7):863-873, 04 Jun 2017
Cited by: 328 articles | PMID: 28592387 | PMCID: PMC5991615
Add to export list Free full text in Europe PMC
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, [...] Robert C
Eur J Cancer, 82:45-55, 22 Jun 2017
Cited by: 101 articles | PMID: 28648698
Add to export list
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, [...] Blumenschein G
J Thorac Oncol, 12(3):556-566, 19 Nov 2016
Cited by: 27 articles | PMID: 27876675
Add to export list
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol, 17(7):984-993, 06 Jun 2016
Cited by: 438 articles | PMID: 27283860 | PMCID: PMC4993103
Add to export list Free full text in Europe PMC
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A, Mookerjee B, Curtis CM, Johnson BE
Lancet Oncol, 17(5):642-650, 11 Apr 2016
Cited by: 236 articles | PMID: 27080216 | PMCID: PMC5006181
Add to export list Free full text in Europe PMC
Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.
Kulkarni D, Song K, Briley L, King K, Dabrowski C, Mookerjee B, Legos J, Spraggs C
Pharmacogenomics, 17(5):459-462, 29 Mar 2016
Cited by: 6 articles | PMID: 27023328
Add to export list
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, [...] Robert C
Lancet Oncol, 16(13):1389-1398, 01 Oct 2015
Cited by: 129 articles | PMID: 26433819
Add to export list

1-25 of 110 results

1 2 3 Next ...

Search life-sciences literature (45,104,206 articles, preprints and more)

Search results

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF^V600E or BRAF^V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG)

RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG)

LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF^V600E-Mutant Colorectal Cancer.

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Dabrafenib plus trametinib in patients with previously untreated BRAF^V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Dabrafenib plus trametinib in patients with BRAF^V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

Partnerships & funding